KRSA

36.9854.33%
TK

Tomas Kiselak

Independent Chairman

Mr. Tomas Kiselak was Director of Zenas BioPharma Limited until June 2026. Mr. Kiselak was Independent Director of Zenas BioPharma, Inc. from September 2020 to May 2026. Mr. Kiselak is Founding Partner of Fairmount Funds Management LLC. He also served as Managing Member from April 2016. He serves as Independent Chairperson of Board at Viridian Therapeutics, Inc. since June 2021. He serves as Independent Director at Jade Biosciences, Inc. since July 2024, at Spyre Therapeutics, Inc. since June 2023 and at Zena BioPharma, Inc. since September 2020. He served as Independent Director of Apogee Therapeutics, Inc. since 2022 until September 3, 2026. He serves as Director of the Korsana board of directors since November 2024. He serves as Independent Chairman of Korsana Biosciences, Inc., Secretary of Quellis Biosciences, Inc., Director of Interius BioTherapeutics, Inc. He also serves as a strategic advisor to Dianthus Therapeutics, Inc. and is a Board Observer of KalVista Pharmaceuticals, Inc., which he joined on July 22, 2015. Previously, Mr. Kiselak served as an Independent Director of Dianthus Therapeutics, Inc. from September 2023 to March 4, 2025. At Viridian Therapeutics, Inc., he also served as Independent Director from October 27, 2020. He was a Managing Director of RA Capital Management, L.P., where he was a part of the research and portfolio management team. He is active in both public and private investments in companies developing drugs, medical devices, diagnostics and research tools. He worked in research laboratories at the Harvard Medical School and was at the Koch Institute at MIT, where he studied the role of autophagy in a diverse set of disorders. He has a B.S. in Economics & Neuroscience from Amherst College.

Positions